Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Orion Rises as Nordea Sees Drug-Pipeline Promise: Helsinki Mover

July 31 (Bloomberg) -- Orion Oyj recouped some of the losses it sustained in Helsinki trading yesterday, when the shares dropped the most in four months, after Nordea Bank AB said potential new products mean clients should buy the stock.

The Finnish drugmaker gained as much as 2.1 percent, the most in a week, in intraday trading. It declined 6 percent yesterday, the most since March 20. Shares in the Espoo, Finland-based company advanced 0.7 percent to 18.33 euros at 3:55 p.m. The volume of shares traded was 27 percent more than the three-month daily average.

“We see no grounds for the 6 percent share price plunge,” Nordea’s Helsinki-based analyst Sami Sarkamies wrote in a note to clients, raising his recommendation to buy from hold. Orion’s Alzheimer’s disease treatment ORM-12741 and prostate cancer medicine ODM-201 have potential for “significant announcements” this year, he said.

Orion is Europe’s least-favored drug stock among analysts amid concerns of generic competition to its Parkinson’s disease drug as patents expire, according to data compiled by Bloomberg. The company has the lowest recommendations on average in the Stoxx 600 Health Care Index, with 9 out of 13 analysts advising clients to sell, the data show.

Mylan Inc., based in Canonsburg, Pennsylvania, was authorized last week to make and sell generic versions of Orion’s proprietary Stalevo treatment for Parkinson’s as the companies settled a patent lawsuit.

The decline in Orion’s Parkinson’s drug sales in the second quarter was offset by growth in other areas, Nordea’s Sarkamies said. Orion’s performance and future partnerships mean the company may have room to raise its guidance this year, he said.

To contact the reporter on this story: Kasper Viita in Helsinki at kviita1@bloomberg.net

To contact the editor responsible for this story: Christian Wienberg at cwienberg@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.